Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorYounossi, Zobair M.
dc.contributor.authorStepanova, Maria
dc.contributor.authorEsteban Mur, Rafael
dc.contributor.authorJacobson, Ira
dc.contributor.authorZeuzem, Stefan
dc.contributor.authorSulkowski, Mark
dc.date.accessioned2021-04-28T10:48:35Z
dc.date.available2021-04-28T10:48:35Z
dc.date.issued2017-02
dc.identifier.citationYounossi ZM, Stepanova M, Esteban R, Jacobson I, Zeuzem S, Sulkowski M, et al. Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity. Medicine (Baltimore). 2017 Feb;96(7):e5914.
dc.identifier.issn 1536-5964
dc.identifier.urihttp://hdl.handle.net/11351/5921
dc.descriptionDirect-acting antivirals; Fatigue; Work productivity
dc.description.abstractPatient-reported outcomes (PROs) such as quality of life and work productivity are important for measuring patient's experience. We assessed PROs during and after treatment of hepatitis C virus (HCV) patients. Data were obtained from a phase 3 open label study of sofosbuvir and ribavirin (SOF + RBV) with and without interferon (IFN). Patients completed 4 PRO assessment instruments (SF-36, Functional Assessment of Chronic Illness Therapy—Fatigue, Chronic Liver Disease Questionnaire— HCV, Work Productivity and Activity—Specific Health Problem) before, during, and after treatment. A total of 533 patients with chronic HCV were enrolled; 28.9% treatment-naïve, 23.1% cirrhotic, 219 received IFN + SOF + RBV and 314 received IFN-free SOF + RBV. At baseline, there were no differences in PROs between the IFN-free and IFN-containing treatment arms (all P > 0.05). During treatment, patients receiving IFN + SOF + RBV had a substantial impairment in their PROs (up to −24.4% by treatment week 12, up to −8.3% at week 4 post-treatment). The PRO decrements seen in the SOF + RBV arm were smaller in magnitude (up to −7.1% by treatment week 12), and all returned to baseline or improved by post-treatment week 4. By 12 weeks after treatment cessation, patients who achieved sustained viral response-12 showed some improvement of PRO scores regardless of the regimen (up to +7.1%, P < 0.0001) or previous treatment experience. In multivariate analysis, the use of IFN was independently associated with lower PROs. IFN-based regimens have a profoundly negative impact to PROs. By contrast, the impact of RBV on these PROs is relatively modest. Achieving HCV cure is associated with improvement of most of the PRO scores.
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofseriesMedicine;96(7)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectVirus de l'hepatitis C
dc.subjectMedicaments - Administració
dc.subjectPacients - Satisfacció
dc.subject.meshHepatitis C, Chronic
dc.subject.mesh/drug therapy
dc.subject.meshQuality of Life
dc.titleSuperiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1097/MD.0000000000005914
dc.subject.decshepatitis C crónica
dc.subject.decs/farmacoterapia
dc.subject.decscalidad de vida
dc.relation.publishversionhttps://journals.lww.com/md-journal/Fulltext/2017/02170/Superiority_of_Interferon_Free_Regimens_for.11.aspx
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Younossi ZM] Department of Medicine, Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA. Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA. [Stepanova M] Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA. Center for Outcomes Research in Liver Diseases (COR-LD), Washington, DC. [Esteban R] Servei de Medicina Interna, Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Jacobson I] Department of Medicine, Mount Sinai Medical Center, New York, NY. [Zeuzem S] Department of Internal Medicine, Goethe University Hospital, Frankfurt, Germany. [Sulkowski M] Department of Medicine, Johns Hopkins University, Baltimore, MD
dc.identifier.pmid28207507
dc.identifier.wos000394432800011
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record